Immunome Receives IND Clearance for IM-1340, Advancing Novel Antibody-Drug Conjugate for Solid Tumors
Immunome, Inc., a clinical-stage targeted oncology company, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340. This clearance allows Immunome to proceed with a Phase 1 first-in-human clinical study for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) designed to treat advanced solid tumors. IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a specific transport receptor found across various solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer. Preclinical studies have shown encouraging anti-tumor activity, including tumor regressions in multiple in vivo models. Immunome anticipates initiating the Phase 1 study in the fourth quarter of 2026.